RESUMO
BACKGROUND: Several biomarkers of gemcitabine effectiveness have been studied in cancers, but less so in hepatocellular carcinoma (HCC), which is identified as the fifth most common cancer worldwide. Investigation of human equilibrative nucleoside transporter-1 (HENT-1) and deoxycytidine kinase (DCK), genes involved in gemcitabine uptake and metabolism, can be beneficial in the selection of potential cancer patients who could be responding to the treatment. AIM: To study HENT-1 and DCK gene expression in HCC patients with different protocols of treatment. METHODS: Using real-time PCR, we analyzed expression levels of HENT-1 and DCK genes from peripheral blood samples of 109 patients (20 controls & 89 HCC patients) between March 2015 and March 2017. All the 89 HCC patients received the antioxidants selenium (Se) and vitamin E (Vit.E) either alone (45 patients) or in combination with gemcitabine (24 patients) or radiofrequency ablation (RFA) (20 patients). RESULTS: There was a significant increase in HENT-1 expression levels in HCC patients treated with Se and Vit.E alone as compared to controls (P Ë .0001), while there was no significant difference between HCC patients treated with gemcitabine or RFA as compared to controls. In contrast, expression of DCK was significantly increased in all groups of HCC patients as compared to controls (P Ë .0001). CONCLUSIONS: HENT-1 and DCK mRNA expressions are important markers of HCC and for GEM effect and GEM sensitivity in patients with HCC. This could be beneficial in the selection of HCC patients sensitive to gemcitabine to avoid subjecting resistant patients to unnecessary chemotherapy.
Assuntos
Carcinoma Hepatocelular , Desoxicitidina Quinase , Desoxicitidina/análogos & derivados , Transportador Equilibrativo 1 de Nucleosídeo , Neoplasias Hepáticas , Antimetabólitos Antineoplásicos/uso terapêutico , Carcinoma Hepatocelular/tratamento farmacológico , Carcinoma Hepatocelular/metabolismo , Estudos Transversais , Desoxicitidina/uso terapêutico , Desoxicitidina Quinase/sangue , Desoxicitidina Quinase/genética , Desoxicitidina Quinase/metabolismo , Egito , Transportador Equilibrativo 1 de Nucleosídeo/sangue , Transportador Equilibrativo 1 de Nucleosídeo/genética , Transportador Equilibrativo 1 de Nucleosídeo/metabolismo , Feminino , Humanos , Neoplasias Hepáticas/tratamento farmacológico , Neoplasias Hepáticas/metabolismo , Masculino , Reação em Cadeia da Polimerase em Tempo Real , Resultado do Tratamento , GencitabinaRESUMO
PURPOSE: Resistance to gemcitabine remains a key challenge in the treatment of pancreatic ductal adenocarcinoma (PDAC), necessitating the constant search for effective strategies for a priori prediction of clinical outcome. While the existing studies focused on aberration of drug disposition genes and proteins as molecular predictors of gemcitabine treatment outcomes, the metabolic aberration associated with chemoresistance in clinical PDAC has been neglected. This exploratory study investigated the potential role of tissue metabolomics in characterizing the clinical treatment outcome of gemcitabine therapy. METHODS: Surgically resected tumors from PDAC patients who underwent gemcitabine-based adjuvant chemotherapy (n = 25) were subjected to metabotyping using gas chromatography/time-of-flight mass spectrometry (GC/TOFMS). RESULTS: A partial least-squares discriminant analysis (PLS-DA) model clearly distinguished patients who had favorable survival [overall survival (OS) > 24 months] from those who exhibited poorer survival (OS < 16 months) (Q 2 = 0.302). Receiver-operating characteristic analysis demonstrated the robustness of the PLS-DA model with an area under the curve of 1. PLS-DA revealed 19 marker metabolites (e.g., lactic acid, proline, and pyroglutamate) that shed insights into the chemoresistance of gemcitabine in PDAC. Particularly, tissue levels of lactic acid complemented transcript expression levels of human equilibrative nucleoside transporter 1 in distinguishing patients according to their overall survival. CONCLUSION: This work established proof-of-principle for GC/TOFMS-based global metabotyping of PDAC and laid the foundation for future discovery of metabolic biomarkers predictive of gemcitabine resistance in PDAC chemotherapy.
Assuntos
Adenocarcinoma/tratamento farmacológico , Antimetabólitos Antineoplásicos/uso terapêutico , Carcinoma Ductal Pancreático/tratamento farmacológico , Desoxicitidina/análogos & derivados , Metabolômica/métodos , Neoplasias Pancreáticas/tratamento farmacológico , Idoso , Biomarcadores , Desoxicitidina/uso terapêutico , Resistencia a Medicamentos Antineoplásicos , Transportador Equilibrativo 1 de Nucleosídeo/sangue , Feminino , Cromatografia Gasosa-Espectrometria de Massas , Regulação Neoplásica da Expressão Gênica/efeitos dos fármacos , Humanos , Ácido Láctico/sangue , Masculino , Pessoa de Meia-Idade , Curva ROC , Estudos Retrospectivos , Análise de Sobrevida , Resultado do Tratamento , GencitabinaRESUMO
Faster acclimatization to high altitude upon re-ascent is seen in humans; however, the molecular basis for this enhanced adaptive response is unknown. We report that in healthy lowlanders, plasma adenosine levels are rapidly induced by initial ascent to high altitude and achieved even higher levels upon re-ascent, a feature that is positively associated with quicker acclimatization. Erythrocyte equilibrative nucleoside transporter 1 (eENT1) levels are reduced in humans at high altitude and in mice under hypoxia. eENT1 deletion allows rapid accumulation of plasma adenosine to counteract hypoxic tissue damage in mice. Adenosine signalling via erythrocyte ADORA2B induces PKA phosphorylation, ubiquitination and proteasomal degradation of eENT1. Reduced eENT1 resulting from initial hypoxia is maintained upon re-ascent in humans or re-exposure to hypoxia in mice and accounts for erythrocyte hypoxic memory and faster acclimatization. Our findings suggest that targeting identified purinergic-signalling network would enhance the hypoxia adenosine response to counteract hypoxia-induced maladaptation.
Assuntos
Aclimatação/fisiologia , Adenosina/metabolismo , Transportador Equilibrativo 1 de Nucleosídeo/metabolismo , Eritrócitos/fisiologia , Hipóxia/fisiopatologia , Receptor A2B de Adenosina/metabolismo , 5'-Nucleotidase/sangue , 5'-Nucleotidase/metabolismo , Adenosina/sangue , Adulto , Altitude , Doença da Altitude/sangue , Doença da Altitude/fisiopatologia , Animais , Proteínas Quinases Dependentes de AMP Cíclico/metabolismo , Transportador Equilibrativo 1 de Nucleosídeo/sangue , Transportador Equilibrativo 1 de Nucleosídeo/genética , Feminino , Proteínas Ligadas por GPI/sangue , Proteínas Ligadas por GPI/metabolismo , Voluntários Saudáveis , Humanos , Hipóxia/sangue , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Knockout , Oxigênio/metabolismo , Fosforilação , Receptor A2B de Adenosina/genética , Transdução de Sinais/fisiologia , Ubiquitinação , Adulto JovemRESUMO
The high-prevalence antigen, Ata, was first identified in 1967, but it was not until 2015 that Ata became AUG1 of a new blood group system, Augustine (AUG). The new system was established after the identification of the gene encoding Ata and the recognition of a null phenotype (AUG:1,2) in an At(a) patient with an antibody (anti-AUG2) reactive with At(a) red blood cells. The At(a) phenotype is very rare and, with the exception of the one family with the null phenotype, has only been found in individuals of African origin. Anti-Ata has been implicated in immediate and delayed hemolytic transfusion reactions, but not in severe hemolytic disease of the fetus and newborn. The Augustine gene is SLC29A1, which encodes the equilibrative nucleoside transporter ENT1. At(a) (AUG:1,2) results from homozygosity for c.1171G>A, encoding Glu391Lys, whereas the AUGnull (AUG:1,2) phenotype results from homozygosity for a splice site mutation, c.589+1G>C, in the only family where it has been found. Absence of ENT1 in that family may be associated with pseudogout and abnormal bone calcification.
Assuntos
Antígenos de Grupos Sanguíneos , Transportador Equilibrativo 1 de Nucleosídeo/sangue , Transporte Biológico , População Negra/genética , Antígenos de Grupos Sanguíneos/genética , Antígenos de Grupos Sanguíneos/imunologia , Doenças Ósseas Metabólicas/sangue , Doenças Ósseas Metabólicas/genética , Condrocalcinose/sangue , Condrocalcinose/genética , Consanguinidade , Teste de Coombs , Transportador Equilibrativo 1 de Nucleosídeo/genética , Transportador Equilibrativo 1 de Nucleosídeo/imunologia , Transportador Equilibrativo 1 de Nucleosídeo/fisiologia , Feminino , Hemólise , Humanos , Recém-Nascido , Isoanticorpos/sangue , Masculino , Modelos Moleculares , Mutação , Linhagem , Fenótipo , Gravidez , Conformação Proteica , Reação TransfusionalRESUMO
Ribavirin [1-(beta-d-ribofuranosyl)-1H-1,2,4-triazole-3-carboxamide] is the treatment of choice for hepatitis C virus infection. Ribavirin is a substrate of several nucleoside transporters, including the equilibrative nucleoside transporter (Ent) and the concentrative nucleoside transporter 2. To determine the role of Ent1 in ribavirin absorption and erythrocyte distribution, we examined its pharmacokinetics in Ent1-null mice. After intravenous administration, we found that the erythrocyte area under the curve (AUC(0-12 h)) was reduced 3.05-fold along with 2.63-fold reduction of erythrocyte versus plasma AUC ratio in the Ent1(-/-) mice, whereas there was no significant difference in the plasma AUC(0-12 h) between Ent1(+/+) and Ent1(-/-) mice. After 48 h, we found a similar fraction of ribavirin or total radioactivity excreted in the urine between the Ent1(+/+) and Ent1(-/-) mice. After oral administration of three different doses, 0.024, 0.24, and 6.1 mg/kg, we found that the dose-normalized plasma AUC(0-12 h) of ribavirin was 69.7 +/- 12.0, 20.7 +/- 1.5, and 18.3 +/- 2.7 min/l, respectively, in the Ent1(+/+) mice and 18.9 +/- 2.8, 13.0 +/- 0.5, and 12.2 +/- 1.0 min/l, respectively, in the Ent1(-/-) mice. It is interesting that at the highest dose, the dose-normalized plasma AUC(0-30 min), AUC(0-12 h), and C(max) in the Ent1(+/+) mice were decreased 4.0-, 3.8-, and 3.4-fold, respectively, compared with the lowest dose, suggesting absorption was saturated at the highest dose we used. The dose-normalized plasma AUC(0-12 h) was 3.7- and 1.5-fold lower at the lowest and the highest dose, respectively, in the Ent1(-/-) mice compared with those of the Ent1(+/+) mice. Our findings indicate that Ent1 plays a significant role in the oral absorption and erythrocyte distribution of ribavirin.
Assuntos
Transportador Equilibrativo 1 de Nucleosídeo/genética , Eritrócitos/metabolismo , Proteínas de Transporte de Nucleosídeos/fisiologia , Ribavirina/administração & dosagem , Absorção/efeitos dos fármacos , Absorção/genética , Administração Oral , Animais , Relação Dose-Resposta a Droga , Transportador Equilibrativo 1 de Nucleosídeo/biossíntese , Transportador Equilibrativo 1 de Nucleosídeo/sangue , Transportador Equilibrativo 1 de Nucleosídeo/farmacocinética , Eritrócitos/efeitos dos fármacos , Feminino , Masculino , Camundongos , Camundongos Knockout , Mucosa Bucal/efeitos dos fármacos , Mucosa Bucal/metabolismo , Proteínas de Transporte de Nucleosídeos/sangue , Ribavirina/sangue , Ribavirina/farmacocinética , Distribuição Tecidual/efeitos dos fármacos , Distribuição Tecidual/genéticaRESUMO
OBJECTIVE: This study investigated nucleoside transport activity and transporter polypeptide expression in erythrocytes from beta-thalassemia major patients to determine if inhibition of transport activity is a sensitive indicator of oxidative membrane damage. MATERIALS AND METHODS: Blood samples were obtained from 54 patients, diagnosed as having beta-thalassemia major prior to therapeutic transfusion, and 20 normal subjects. Uptake of (3)H-uridine into washed erythrocytes was measured at room temperature using short incubation periods (5 s) and a rapid inhibitor oil stop protocol. Erythrocyte membranes were analyzed by SDS-PAGE and nucleoside (hENT1) and glucose (GLUT-1) transporter polypeptides quantitated on immunoblots. RESULTS: Uridine uptake was significantly lower in beta-thalassemic cells than in normal erythrocytes (20.03 +/- 1.08 pmol/10(8) cells/ 5 s, mean +/- SEM, n = 31, vs. 31.15 +/- 1.21 pmol/10(8) cells/5 s, n = 20; p < 0.0001). Expression of hENT1 was significantly lower in beta-thalassemic cells (23.90 +/- 1.01 arbitrary units, n = 54) than in controls (101.20 +/- 2.43 arbitrary units, n = 20; p < 0.001) but expression of GLUT-1 was not changed appreciably (101.80 +/- 2.43 arbitrary units, n = 54, for thalassemic cells; 102.60 +/- 3.02 arbitrary units, n = 20, for control cells; p = 0.87). CONCLUSIONS: Erythrocytes from beta-thalassemia major patients showed decreased uridine transport which was associated with decreased nucleoside transporter expression. The process(es) mediating a selective decrease in hENT1 polypeptides in beta-thalassemia major was/were not determined.